CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD
Status:
Not yet recruiting
Trial end date:
2022-11-26
Target enrollment:
Participant gender:
Summary
Double Blind, Multinational, Multicentre, Randomised, Placebo-Controlled, 3-Way Cross-Over
Study To Evaluate The Effect Of A Triple Combination Of Beclometasone Dipropionate And
Formoterol Fumarate Plus Glycopyrronium (CHF5993) And A Dual Combination Of Beclometasone
Dipropionate Plus Formoterol Fumarate (CHF1535) Both Administered Via pMDI On Lung
Hyperinflation And Exercise Endurance Time In Subjects With Chronic Obstructive Pulmonary
Disease (COPD)